- Home
- CCI vs ROIV Comparison
CCI vs ROIV Comparison
Compare CCI & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CCI | ROIV |
|---|---|---|
| Founded | 1994 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.3B | 26.2B |
| IPO Year | 1998 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CCI | ROIV |
|---|---|---|
| Price | $73.81 | $36.09 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 9 |
| Target Price | ★ $104.69 | $28.94 |
| AVG Volume (30 Days) | 4.3M | ★ 5.0M |
| Earning Date | 04-22-2026 | 05-28-2026 |
| Dividend Yield | ★ 4.95% | N/A |
| EPS Growth | ★ 111.25 | N/A |
| EPS | ★ 0.56 | N/A |
| Revenue | ★ $4,264,000,000.00 | $8,260,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.72 | $744.61 |
| P/E Ratio | $131.50 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $69.72 | $11.54 |
| 52 Week High | $104.61 | $37.00 |
Technical Indicators
Market Signals| Indicator | CCI | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 40.75 | 59.75 |
| Support Level | $69.72 | $33.01 |
| Resistance Level | $89.76 | $36.35 |
| Average True Range (ATR) | 2.79 | 1.24 |
| MACD | 0.02 | 0.09 |
| Stochastic Oscillator | 40.13 | 87.36 |
Price Performance
Historical ComparisonAbout CCI Crown Castle Inc.
Crown Castle owns or manages roughly 40,000 wireless towers in the United States. It leases space on its towers to wireless service providers, which install equipment to support their wireless networks. The company has a very concentrated customer base, with about 90% of its revenue from the Big Three US mobile carriers: Verizon, T-Mobile, and AT&T. Crown Castle has plans to divest its fiber business, which is expected to be finalized in the first half of 2026. After that, it will be a stand-alone tower operator. Crown Castle operates as a real estate investment trust.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.